ArticleJournal of shoulder and elbow surgery2025
Inferior Glenoid HyperOSTosis (GHOST) lesion development following reverse total shoulder arthroplasty.
Article in Journal of shoulder and elbow surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatients undergoing reverse total shoulder arthroplasty (rTSA) have been noted on postoperative radiographs to have a curved bony overgrowth on the inferior glenoid neck. This study aims to investigate potential risk factors for and postoperative effects of these ossifications, here called Glenoid HyperOSTosis (GHOST) lesions because of their location.
methodsA retrospective review of patients undergoing rTSA between 2007 and 2020 at a single institution was performed. Predictors, including gender, age, implant sizing, and preoperative diagnosis, were examined using logistic regression analysis. Outcomes including readmission rate, revision rate, preoperative and postoperative range of motion, visual analog scale (VAS) pain scores, and American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) functional outcome scores were also analyzed using 2-sample t tests.
resultsPreoperative and postoperative radiographs of 170 primary rTSA patients were assessed. One-fourth (25.9%) of rTSAs were identified to have a GHOST lesion. When adjusting for race, age, body mass index (BMI), and preoperative diagnosis, male patients were still associated with 2.28 odds of developing a GHOST lesion compared with female patients (95% confidence interval [CI] 1.08-4.86). Other elements such as age, race, BMI, laterality, preoperative diagnosis, implant manufacturer, and implant sizing demonstrated no statistically significant association with GHOST lesion presence. Postoperatively, GHOST lesion development was not associated with range of motion or ASES score. However, presence of GHOST lesions on radiographs was associated with increased pain scores for patients at 2 months (P = .034) and 12 months (P = .029) postoperatively. DISCUSSION: Inferior GHOST lesions are a common and potentially benign finding following rTSA, with unclear etiology. Risk factors for GHOST lesions included male gender, whereas patient demographics, implant type or size, shoulder lateralization, and distalization were not associated with lesion formation. Clinically, greater short-term VAS scores were seen in patients with GHOST lesions. However, there were no differences observed between the 2 groups in ASES scores or postoperative range of motion at later time points. Further research is needed to identify risk factors and assess the clinical implications of GHOST lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.